Halozyme Therapeutics (NASDAQ:HALO) CEO Helen Torley Sells 1,923 Shares of Stock

Posted by Francis Steltz on Jul 10th, 2026

Halozyme Therapeutics, Inc. (NASDAQ:HALO – Get Free Report) CEO Helen Torley sold 1,923 shares of the company’s stock in a transaction on Wednesday, July 8th. The shares were sold at an average price of $79.77, for a total value of $153,397.71. Following the completion of the sale, the chief executive officer owned 767,780 shares of the company’s stock, valued at approximately $61,245,810.60. The trade was a 0.25% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Helen Torley also recently made the following trade(s):

On Wednesday, June 3rd, Helen Torley sold 10,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $69.07, for a total transaction of $690,700.00.
On Monday, June 1st, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $67.58, for a total transaction of $1,351,600.00.
On Wednesday, May 13th, Helen Torley sold 10,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $69.19, for a total value of $691,900.00.
On Tuesday, May 12th, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $71.75, for a total transaction of $1,435,000.00.

Halozyme Therapeutics Price Performance

Halozyme Therapeutics stock opened at $78.62 on Friday. The company has a market capitalization of $9.33 billion, a price-to-earnings ratio of 28.28, a price-to-earnings-growth ratio of 0.33 and a beta of 0.84. The company has a debt-to-equity ratio of 8.81, a quick ratio of 2.33 and a current ratio of 2.76. Halozyme Therapeutics, Inc. has a 1 year low of $55.64 and a 1 year high of $82.26. The company’s 50 day simple moving average is $70.63 and its 200-day simple moving average is $69.87.

Halozyme Therapeutics (NASDAQ:HALO – Get Free Report) last released its quarterly earnings results on Monday, May 11th. The biopharmaceutical company reported $1.60 EPS for the quarter, topping the consensus estimate of $1.54 by $0.06. Halozyme Therapeutics had a return on equity of 187.91% and a net margin of 23.13%.The business had revenue of $376.71 million during the quarter, compared to analyst estimates of $358.60 million. During the same period last year, the business posted $1.11 earnings per share. The company’s quarterly revenue was up 42.2% on a year-over-year basis. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. As a group, equities research analysts expect that Halozyme Therapeutics, Inc. will post 7.54 earnings per share for the current year.

Analyst Upgrades and Downgrades

HALO has been the topic of several recent research reports. Benchmark restated a “buy” rating on shares of Halozyme Therapeutics in a report on Wednesday, June 3rd. UBS Group reissued a “buy” rating and issued a $90.00 price target on shares of Halozyme Therapeutics in a research report on Wednesday, June 3rd. Weiss Ratings upgraded Halozyme Therapeutics from a “hold (c)” rating to a “buy (b-)” rating in a research note on Tuesday, May 12th. Wall Street Zen upgraded shares of Halozyme Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, May 16th. Finally, HC Wainwright reiterated a “buy” rating on shares of Halozyme Therapeutics in a research report on Tuesday, June 16th. Eight investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $81.60.

Read Our Latest Analysis on Halozyme Therapeutics

Hedge Funds Weigh In On Halozyme Therapeutics

Several hedge funds have recently added to or reduced their stakes in HALO. Measured Wealth Private Client Group LLC grew its position in shares of Halozyme Therapeutics by 51.5% in the fourth quarter. Measured Wealth Private Client Group LLC now owns 365 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 124 shares during the last quarter. Larson Financial Group LLC raised its position in shares of Halozyme Therapeutics by 3,118.2% during the 3rd quarter. Larson Financial Group LLC now owns 354 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 343 shares during the last quarter. Harbour Investments Inc. raised its position in shares of Halozyme Therapeutics by 152.5% during the 4th quarter. Harbour Investments Inc. now owns 616 shares of the biopharmaceutical company’s stock worth $41,000 after purchasing an additional 372 shares during the last quarter. Clearstead Advisors LLC lifted its stake in Halozyme Therapeutics by 64.8% in the 4th quarter. Clearstead Advisors LLC now owns 842 shares of the biopharmaceutical company’s stock valued at $57,000 after buying an additional 331 shares in the last quarter. Finally, Wexford Capital LP acquired a new stake in Halozyme Therapeutics during the 3rd quarter valued at $70,000. 97.79% of the stock is currently owned by hedge funds and other institutional investors.

About Halozyme Therapeutics

(Get Free Report)

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.